Oligopeptide-1: evidence, FDA status and research

An ingredient in skin serums sold to renew skin and soften fine lines. It has only been tested in a few small studies, such as 18 people without a comparison group.

Sold for

Oligopeptide-1 is sold in growth-factor serums promising faster skin renewal, firmer texture and fewer fine lines.

Studies say

EGF has a well-understood role in wound healing, but the cosmetic evidence is a handful of small, short, uncontrolled or industry-run studies, which is C-grade support.

Why grade C. The human evidence in these sources is an open pilot study of an EGF serum in 18 volunteers with no control group. Larger controlled trials of oligopeptide-1 as a cosmetic have not been identified, and those that exist test it inside multi-ingredient products. Uncontrolled series put it at C. ¹

FDA. Oligopeptide-1 is the cosmetic ingredient name for epidermal growth factor. In skincare it is regulated as a cosmetic and is not approved by the FDA as a drug for any use; the FDA does not approve cosmetic ingredients before sale. ²³

Written from 3 cited sources. Fact-checked 2026-10-27: 8 claims checked, 0 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Renewing skin and smoothing fine lines.
Can a US doctor prescribe it?: No prescription; it is a cosmetic ingredient.
Properly tested in people?: Not properly: animal or lab studies, or small uncontrolled human reports. one 18-person study with no comparison group.

Evidence checklist

Randomised controlled trial Open pilot only, no control groupno
Human study over 100 people Pilot had 18 volunteersno
More than one research group Other studies use multi-ingredient productsno
Clinical outcomes, not surrogate markers Investigator-graded under-eye bagsno
Human safety data beyond case reports Small, short studies; long-term unknownno

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Oligopeptide-1 is the INCI label name for epidermal growth factor (EGF). EGF is a protein of 53 amino acids. The body uses it to tell skin cells to divide and move. Cosmetic versions are made by recombinant methods in bacteria, yeast or plants. That is why labels sometimes read sh-oligopeptide-1 (synthetic human) or rh-oligopeptide-1 (recombinant human). ¹³

The discovery of EGF won a Nobel Prize in 1986. Recombinant EGF has been used medically for burns and diabetic ulcers in several countries. Cosmetic use borrows that reputation. In the United States, a product containing it is a cosmetic. If it claims to treat a condition, it would be an unapproved drug. ²³

How it works

EGF binds the EGF receptor on keratinocytes and fibroblasts. This triggers signaling. Cells divide and move more. They also make more matrix proteins such as collagen. In a wound, this speeds closure. The cosmetic claim is that the same signal does more on intact aging skin. It is said to thicken the epidermis and improve texture. The open question is penetration. EGF is a large, water-soluble protein. Intact skin is built to keep such molecules out. ¹

What human research shows

The one human study found is a 2015 open pilot. 18 volunteers applied an EGF serum twice daily to the under-eye area. 16 completed it. Investigator grading showed a significant drop in under-eye bag severity. Most participants reported improvement. There was no placebo or vehicle control. So the effect of EGF cannot be told apart from the base formulation and the act of regular application. ¹

Other published work tests EGF in skincare along with lasers, hyaluronic acid or antioxidant blends. That says something about the product. It says little about the peptide alone. These sources do not identify a controlled trial of oligopeptide-1 alone in aging skin. ¹

Study	Model	Finding
EGF serum under-eye pilot (2015)	Humans, n=18 volunteers, open-label, no control	Twice-daily EGF serum reduced investigator-graded under-eye bag severity over the study period. ¹
FDA cosmetic versus drug guidance	Regulatory document	A topical product is a cosmetic or a drug depending on its claims; cosmetics are not pre-approved. ³

Safety

The pilot reported good tolerability, with no serious adverse events. The theoretical concern with a growth factor is that it pushes cells to divide without discrimination. That is why dermatologists have raised questions about long-term use. The worry is greatest on sun-damaged skin or near skin cancers. No published evidence shows harm from cosmetic use. No published evidence rules it out either. The studies are too small and too short. ¹²

Questions for your clinician

Is there a controlled trial of oligopeptide-1 alone?
Is a growth-factor product sensible with sun-damaged skin?
Which ingredients have stronger evidence for my goal?

Questions people ask

Is oligopeptide-1 the same as EGF?

Yes. Oligopeptide-1 is the cosmetic ingredient name for epidermal growth factor. Prefixes such as sh- or rh- show it was made by recombinant methods. It was not extracted from tissue. ¹

Can a growth factor cause skin cancer?

No published study shows that cosmetic EGF does. The concern is theoretical. EGF receptor signaling is overactive in some cancers. So stimulating it on sun-damaged skin is a fair question. The small, short cosmetic studies cannot answer it. ¹²

Does it penetrate the skin?

EGF is a large protein, and intact skin blocks most molecules of that size. Products often pair it with penetration boosters. Some recommend use after microneedling. That also changes the safety picture. These sources lack direct measures of how much reaches living skin layers from a cosmetic serum. ¹

Citations

Seidel 2015, J Drugs Dermatol: reduced appearance of under-eye bags with twice-daily application of EGF serum, a pilot study pubmed.ncbi.nlm.nih.gov
FDA: how cosmetics are not FDA-approved but are FDA-regulated fda.gov
FDA: is it a cosmetic, a drug, or both? fda.gov